CA-INSEEGO
31.3.2021 15:07:07 CEST | Business Wire | Press release
Inseego Corp. (Nasdaq: INSG), a leader in 5G and IoT device-to-cloud solutions, today announced that its Wavemaker PRO 5G indoor router FX2000e has been certified for use in several markets globally. This plug-and-play fixed wireless solution provides 5G/LTE broadband with ethernet and Wi-Fi 6 connectivity for up to 32 devices, making it ideal for small businesses and distributed employees who need fast, reliable and highly secure internet access.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005341/en/
With gigabit-class 5G speeds, the FX2000e delivers fast, reliable connectivity almost anywhere, from restaurant and retail locations to branch offices and home offices. The Inseego Mobile app provides an intuitive UI and makes it easy for end users to self-install their devices. Using Inseego Connect cloud softwarei , IT managers can remotely configure and manage all devices in a highly scalable deployment.
“5G solutions provide a great choice for broadband access for businesses and consumers in their distributed offices and homes,” said Inseego President of IoT & Mobile Solutions Ashish Sharma. “Our FX2000e is a compact solution that supports many different use cases for broadband connectivity: Small businesses can get fast internet access anywhere. Enterprises can easily deploy a secure WAN solution for their branch offices and remote employees. And SD WAN providers can now rely on a 5G WAN connection as a primary broadband connection for distributed locations.”
Flexible 5G connectivity
The FX2000e is certified to operate in a broad range of global 5G and 4G frequency bands. Designed as a powerful and cost-effective solution for last-mile internet access, it can bring high-speed broadband connectivity to users on leading 4G and 5G networks in global markets.
With its small form factor, the FX2000e can be deployed as the primary broadband solution for distributed retail locations, as an add-on WAN interface for SD WAN deployments, as an internet solution for small occupancy homes, or as a cable modem replacement for larger homes with mesh Wi-Fi systems and other connectivity needs.
Fast, flexible, reliable and secure
- Gigabit-class 5G and LTE speeds
- Robust connectivity with ethernet and Wi-Fi 6 for up to 32 devices
- Dual-SIM functionality for up to two carrier SIMs, with auto-switching between cellular networks and ethernet WAN
- Enterprise-grade security with OpenVPN, access control, end-to-end device security, threat identification, monitoring, threat alerts and other protectionsii
- Inseego Connect™ Advanced cloud management
- Continuous software updates, security and support
Availability
The Inseego Wavemaker™ PRO 5G indoor CPE FX2000e has received regulatory certifications for use in several regions worldwide, including FCC Band 48 support for CBRS networks, and is now available through major distributors in North America and Europe. Please contact Inseego to learn more.
A broad portfolio of 5G FWA solutions for consumers and enterprise customers
In addition to the FX2000e, the Inseego Wavemaker PRO portfolio includes the 5G indoor CPE FG2000e, which is currently commercially available in several markets. The portfolio also includes two 5G outdoor CPEs and a 5G industrial gateway. Please contact Inseego to learn more about these solutions.
Trusted and secure
Designed and developed in the U.S., Inseego solutions are trusted by leading mobile operators, government agencies and enterprise customers worldwide. To learn more about Inseego 5G products and solutions go to inseego.com . For press and analyst inquires, please email press@inseego.com .
About Inseego Corp.
Inseego Corp. (Nasdaq: INSG) is an industry leader in smart device-to-cloud solutions that extend the 5G network edge, enabling broader 5G coverage, multi-gigabit data speeds, low latency and strong security to deliver highly reliable internet access. Our innovative mobile broadband, fixed wireless access (FWA) solutions, and software platform incorporate the most advanced technologies (including 5G, 4G LTE, Wi-Fi 6 and others) into a wide range of products that provide robust connectivity indoors, outdoors and in the harshest industrial environments. Designed and developed in the USA, Inseego products and SaaS solutions build on the company’s patented technologies to provide the highest quality wireless connectivity for service providers, enterprises, and government entities worldwide. www.inseego.com #Putting5GtoWork
©2021 Inseego Corp. All rights reserved. The Inseego name and logo are registered trademarks, and the Wavemaker and Inseego Manage names are trademarks of Inseego Corp.
________________
i
Base version (free) enables a user to manage a single FX2000e device settings easily using the Inseego Mobile app or Web UI. For management of multiple devices, an Inseego Connect Standard or Inseego Connect Advanced subscription is required, providing advanced device management, provisioning, monitoring, and diagnostics for multiple devices from a single dashboard.
ii Contact Inseego to learn more about available advanced security solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005341/en/
Link:
Social Media:
https://www.facebook.com/Inseego/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom